What's New in CLL Post ASCO 2019: BCL-2 Inhibitors

 

What's New in CLL Post ASCO 2019: BCL-2 Inhibitors
08:34

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019: Update on CLL Preferred Therapy - Venetoclax + Obinutuzumab

FEATURING Marc Hoffmann
  • 936 views
  • August 19, 2019
  • 4
09:35

ERIC Workshop on MRD Analysis in Chronic Lymphocytic Leukemia

CLL Imaging with Targeted Therapies - Study of Venetoclax/Rituximab & Venetoclax/Obinutuzumab and Significance of MRD-

FEATURING Peter Hillmen
  • 431 views
  • June 26, 2019
  • 1
28:14

What's New in CLL Post ASCO 2019: BCL-2 Inhibitors

Combining Novel Agents in Chronic Lymphocytic Leukemia: Greater Than the Sum of its Parts?

FEATURING Arnon Kater
  • 275 views
  • August 21, 2019
  • 1